肝病中微生物组的治疗性调控
本文综述了微生物组作为肠-肝轴介质的功能与机制角色,并梳理了从益生元、益生菌、合生元、抗生素到微生物组重建和精准微生物组工程等多层次干预策略。文章结合临床前动物模型、人体研究和临床试验数据,讨论了这些疗法在代谢功能障碍相关脂肪性肝病、酒精相关性肝病、肝硬化、肝性脑病及肝癌中的潜在应用与理论基础,并总结了既往开发经验、监管框架和剩余挑战。
要点
- 微生物组功能活性是多种肝病有吸引力的精准医学治疗靶点。
- 干预层次涵盖益生元、益生菌、合生元、抗生素、微生物组重建和精准微生物组工程。
- 综述整合临床前动物模型、人体研究和临床试验数据,覆盖脂肪性肝病、酒精相关性肝病、肝硬化、肝性脑病及肝癌。
核心结论
- 基于微生物组作为肠-肝轴介质的机制,其功能活性是多种肝病中有吸引力、可操作且精准医学导向的治疗靶点。
- 要将成功的微生物组靶向和微生物组启发疗法推向临床,需全面理解影响、协作或工程化肠道微生物组以利用疾病相关功能的不同方法,并匹配正确患者。
研究设计与样本
- 综述类文章,检索范围未在原文中明确报告。
主要发现
- 文献已描述微生物组与肝脏生理和病理多个方面之间的无数关联。
- 在描述性和相关性测序研究基础上,宏基因组研究正在扩展对微生物组作为肠-肝轴介质的功能和机制角色的集体理解。
- 若干治疗已在肝病中使用,甚至早于它们被描述为微生物组依赖方法。
关键数值与推荐
- 原文未报告具体标准或数值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myriad associations between the microbiome and various facets of liver physiology and pathology have been described in the literature. Building on descriptive and correlative sequencing studies, metagenomic studies are expanding our collective understanding of the functional and mechanistic role of the microbiome as mediators of the gut-liver axis. Based on these mechanisms, the functional activity of the microbiome represents an attractive, tractable, and precision medicine therapeutic target in several liver diseases. Indeed, several therapeutics have been used in liver disease even before their description as a microbiome-dependent approach. To bring successful microbiome-targeted and microbiome-inspired therapies to the clinic, a comprehensive appreciation of the different approaches to influence, collaborate with, or engineer the gut microbiome to coopt a disease-relevant function of interest in the right patient is key. Herein, we describe the various levels at which the microbiome can be targeted-from prebiotics, probiotics, synbiotics, and antibiotics to microbiome reconstitution and precision microbiome engineering. Assimilating data from preclinical animal models, human studies as well as clinical trials, we describe the potential for and rationale behind studying such therapies across several liver diseases, including metabolic dysfunction-associated steatotic liver disease, alcohol-associated liver disease, cirrhosis, HE as well as liver cancer. Lastly, we discuss lessons learned from previous attempts at developing such therapies, the regulatory framework that needs to be navigated, and the challenges that remain.
引用
- Parthasarathy G, Malhi H, Bajaj JS, et al. Therapeutic manipulation of the microbiome in liver disease. Hepatology. 2024. PMID: 38922826. doi:10.1097/HEP.0000000000000987
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。